Water, Sanitation and Hygiene Services
APAC
Updated
Reviewed by Vidhi Upadhyay
APAC Biologics CDMO Market Industry Trends and Forecast to 2034: Segmented by (Product, Service, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$10.11 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $4.82 Bn | — | — |
| 2025 (base) | $5.42 Bn | +$598.2 Mn | — |
| 2026 (forecast) | $6.10 Bn | +$672.4 Mn | +12.4% |
| 2027 (forecast) | $6.85 Bn | +$755.8 Mn | +26.3% |
| 2028 (forecast) | $7.70 Bn | +$849.5 Mn | +42% |
| 2029 (forecast) | $8.66 Bn | +$954.8 Mn | +59.6% |
| 2030 (forecast) | $9.73 Bn | +$1.07 Bn | +79.4% |
| 2031 (forecast) | $10.93 Bn | +$1.21 Bn | +101.6% |
| 2032 (forecast) | $12.29 Bn | +$1.36 Bn | +126.7% |
| 2033 (forecast) | $13.81 Bn | +$1.52 Bn | +154.8% |
| 2034 (forecast) | $15.53 Bn | +$1.71 Bn | +186.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $5.42 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $15.53 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 12.4% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Also called | Biologics Contract Development and Manufacturing (CDMO) |
| Segments | Product, service and end user (see all) |
| Key players | Lonza Ltd, Samsung Biologics, WuXi Biologics, FUJIFILM Holdings Corporation, Catalent and 1 more (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Biologics CDMOs develop and manufacture antibodies, proteins and vaccines for pharma and biotech companies.
Key segments of the biologics CDMO market include product (Monoclonal Antibodies, Recombinant Proteins and Vaccines) and service (Process Development, Clinical Manufacturing and Commercial Manufacturing).
Growing drug pipelines, more complex biologics, cost pressure on drug makers and the need for speed are driving the biologics CDMO market. Many companies now outsource work they used to do in-house.
Advanced therapies, AI-driven operations and expansion in India, China and Southeast Asia give the biologics CDMO market room to grow.
Capacity shortages, strict quality rules, data security concerns and pricing pressure hold back the biologics CDMO market.
The biologics CDMO market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
How care is paid for in some of these countries: Medicare and the PBS (Australia)[1], basic medical insurance (China)[2], the Hospital Authority (Hong Kong)[3], Ayushman Bharat PM-JAY (India)[4], public health insurance (Japan)[5], subsidised public care (Malaysia)[6], Pharmac (New Zealand)[7], PhilHealth (Philippines)[8], MediShield Life (Singapore)[9] and the Universal Coverage Scheme (Thailand)[10].
[1] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
[2] National Healthcare Security Administration. Checked 14 Nov 2026.
[3] Hospital Authority. Checked 14 Nov 2026.
[4] National Health Authority (PM-JAY). Checked 14 Nov 2026.
[5] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
[6] Ministry of Health Malaysia. Checked 14 Nov 2026.
[7] Pharmac. Checked 14 Nov 2026.
[8] PhilHealth. Checked 14 Nov 2026.
[9] CPF Board, MediShield Life. Checked 14 Nov 2026.
[10] National Health Security Office. Checked 14 Nov 2026.
Licensing, quality standards and payment models from public and private payers shape how biologics CDMO services are delivered and paid for in APAC. Government health programs and insurance coverage are key to access.
From our blog
Pharmaceuticals · APAC
Pharmaceuticals · APAC
Pharmaceuticals · APAC
Medical Devices · APAC
Pharmaceuticals · APAC
Pharmaceuticals · APAC